[1]郑士航,张飞飞,高曼,等.急性ST，段抬高型心肌梗死患者经皮冠状动脉介入术后无复流的研究进展[J].国际心血管病杂志,2022,01:32-35.
点击复制
急性ST，段抬高型心肌梗死患者经皮冠状动脉介入术后无复流的研究进展(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年01期
- 页码:
- 32-35
- 栏目:
- 综述
- 出版日期:
- 2022-02-10
文章信息/Info
- Title:
- -
- 作者:
- 郑士航; 张飞飞; 高曼; 王禹丹; 李英肖; 党懿; 齐晓勇
- 作者单位：075000 张家口，河北北方学院研究生院( 郑士航) ； 050051 石家庄，河北省人民医院心内科（齐晓勇，党懿，李英肖， 张飞飞，高曼）；050017 石家庄，河北医科大学研究生院（王禹丹）
- Author(s):
- -
- 关键词:
- 急性ST 段抬高型心肌梗死; 无复流; 缓血流; 经皮冠脉介入术
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.01.009
- 文献标识码:
- -
- 摘要:
- 约1/3 的急性ST 段抬高型心肌梗死患者接受直接经皮冠状动脉介入术后出现 无复流。无复流的常用诊断方法是冠状动脉造影，治疗和预防策略主要包括降低血栓负荷、 改善微循环功能、减轻缺血再灌注损伤及诱导受损心肌再生。该文介绍急性ST 段抬高型心 肌梗死患者经皮冠状动脉介入术后无复流的治疗进展。
- Abstract:
- -
参考文献/References
[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员
会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019) [J]. 中
华心血管病杂志, 2019, 10(47):766-783.
[2] Szummer K, Wallentin L, Lindhagen L, et al. Improved
outcomes in patients with ST-elevation myocardial infarction
during the last 20years are re lated to implementation
of evidence-based treatments: experiences from the
SWEDEHEART registry 1995-2014[J]. Eur Heart J, 2017,
38(41):3056-3065.
[3] Okamura A, Ito H, Iwakura K, et al. Detection of embolic
particles with the Doppler guide wire during coronary
intervention in patients with acute myocardial infarction:
efficacy of distal protection device[J]. J Am Coll Cardiol,
2005, 45(2):212-215.
[4] Kloner RA, Ganote CE, Jennings RB. The "no-reflow"
phenomenon after temporary coronary occlusion in the dog[J].
J Clin Invest, 1974, 54(6):1496-1508.
[5] Fujiwara H, Onodera T, Tanaka M, et al. A clinicopathologic
study of patients with hemorrhagic myocardial infarction
treated with selective coronary thrombolysis with urokinase[J].
Circulation, 1986, 73(4):749-757.
[6] Huang MH, Loh PH, Tan HC, et al. Reducing reperfusion
injury during percutaneous coronary intervention[J]. Singapore
Med J, 2019, 60(12):608-609.
[7] Jolly SS, Cairns JA, Yusuf S, et al. Stroke in the TOTAL trial:
a randomized trial of routine thrombectomy vs. percutaneous
coronary intervention alone in ST elevation myocardial
infarction[J]. Eur Heart J, 2015, 36(35):2364-2372.
[8] Jolly SS, James S, D?avík V, et al. Thrombus aspiration in STsegment-
elevation myocardial infarction: an individual patient
Meta-Analysis: thrombectomy trialists collaboration[J].
Circulation, 2017, 135(2):143-152.
[9] Kelbaek H, Terkelsen CJ, Helqvist S, et al. Randomized
comparison of distal protection versus conventional treatment
in primary percutaneous coro nary intervention:the drug
elution and distal protection in ST-elevation myocardial
infarction(DED ICATION)trial[J]. J Am Coll Cardiol, 2008,
51(9):899-905.
[10] Hibi K, Kozuma K, Sonoda S, et al. A randomized study
of distal filter protection versus conventional treatment
during percutaneous Coro nary intervention in patients with
attenuated plaque identified by intravascular ultrasound[J].
JACC Cardiovasc Interv, 2018, 11(16):1545-1555.
[11] Topaz O, Ebersole D, Das T, et al. Excimer laser angioplasty
in acute myocardial infarction (the CARMEL multicenter trial)
[J]. Am J Cardiol, 2004, 93(6):694-701.
[12] Nishino M, Mori N, Takiuchi S, et al. Indications and
outcomes of excimer laser coronary atherectomy: efficacy and
safety for thrombotic le sions—the ULTRAMAN registry[J]. J
Cardiol, 2017, 69(1):314-319.
[13] Karacsonyi J, Armstrong EJ, Truong HTD, et al. Contemporary
use of laser during percutaneous coronary interventions:
insights from the laser veterans affairs (LAVA) multicenter
registry[J]. J Invasive Cardiol, 2018, 30(6):195-201.
[14] Thiele H, W?hrle J, Hambrecht R, et al. Intracoronary versus
intravenous bolus abciximab during primary percutaneous
coronary intervention in patients with acute ST-elevation
myocardial infarction: a randomised trial[J]. Lancet, 2012,
379(9819):923-931.
[15] Zaki T, Labib S, El-Abbady M, et al. Local intracoronary
infusion of glycoprotein Ⅱb/Ⅲa inhibitors via a perfusion
catheter versus intracoronary guiding catheter injection
during primary percutaneous coronary intervention: a pilot
Observational study[J]. Acta Cardiol Sin, 2017, 33(3):258-265.
[16] Park K, Cho YR, Park JS, et al. Comparison of the effects
of ticagrelor and clopidogrel on microvascular dysfunction
in patients with acute coronary syndrome using invasive
physiologic indices[J]. Circ Cardiovasc Interv, 2019,
12(10):e008105.
[17] Dai W, Ye Z, Li L, et al. Effect of preoperative loading dose
ticagrelor and clopidogrel on no-reflow phenomenon during
intervention in patients with ST-segment elevation myocardial
infarction undergoing primary percutaneous coronary
intervention: a systematic review and meta-analysis[J]. Drug
Des Devel Ther, 2018, 12:2039-2049.
[18] Alyamani M, Campbell S, Navarese E, et al. Safety and
efficacy of intracoronary thrombolysis as adjunctive therapy to
primary PCI in STEMI: a systematic review and meta-analysis
[J]. Can J Cardiol, 2021, 37(2):339-346.
[19] De Maria GL, Kassimis G, Raina T, et al. Reconsidering
the back door approach by targeting the coronary sinus in
ischaemic heart disease[J]. Heart, 2016, 102(16):1263-1269.
[20] De Maria GL, Alkhalil M, Borlotti A, et al. Index of
microcirculatory resistance-guided therapy with pressurecontrolled
intermittent coronary sinus occlusion improves
coronary microvascular function and reduces infarct size in
patients with ST-elevation myocardial infarction: the Oxford
Acute Myocardial Infarction-Pressure-controlled Intermittent
Coronary Sinus Occlusion study (OxAMI-PICSO study)[J].
EuroIntervention, 2018, 14(3):e352-e359.
[21] Wang L, Cheng Z, Gu Y, et al. Short-term effects of verapamil
and diltiazem in the treatment of no reflow phenomenon: a
meta-analysis of randomized controlled trials[J]. Biomed Res
Int, 2015, 2015:382086.
[22] Fischell T, Haller S, Pulukurthy S, et al. Nicardipine and
adenosine "flush cocktail" to prevent no-reflow during
rotational atherectomy[J]. Cardiovasc Revasc Med, 2008,
9(4):224-228.
[23] Niccoli G, Spaziani C, Crea F, et al. Left ventricular
remodeling and 1-year clinical follow-up of the REOPENAMI
trial[J]. J Am Coll Cardiol, 2014, 63(14):1454-1455.
[24] Nazir SA, Mccann GP, Greenwood JP, et al. Strategies to
attenuate micro-vascular obstruction during P-PCI: the
randomized reperfusion facilitated by local adjunctive therapy
in ST-elevation myocardial infarction trial[J]. Eur Heart J,
2016, 37(24):1910-1919.
[25] Kalla M, Hao G, Tapoulal N, et al. The cardiac sympathetic
co-transmitter neuropeptide Y is pro-arrhythmic following STelevation
myocardial infarction despite beta-blockade[J]. Eur
Heart J, 2020, 41(23):2168-2179.
[26] Herring N, Tapoulal N, Kalla M, et al. Neuropeptide-Y causes
coronary microvascular constriction and is associated with
reduced ejection fraction following ST-elevation myocardial
infarction[J]. Eur Heart J, 2019, 40(24):1920-1929.
[27] Sheng X, Ding S, Ge H, et al. Intracoronary infusion
of alprostadil and nitroglycerin with targeted perfusion
microcatheter in STEMI patients with coronary slow flow
phenomenon[J]. Int J Cardiol, 2018, 265:6-11.
[28] Huang YY, Wu JM, Su T, et al. Fasudil, a Rho-Kinase
inhibitor, exerts cardioprotective function in animal models of
myocardial ischemia/reperfusion injury: a meta-analysis and
review of preclinical evidence and possible mechanisms[J].
Front Pharmacol, 2018, 9:1083.
[29] Kikuchi Y, Takahashi J, Hao K, et al. Usefulness of
intracoronary administration of fasudil, a selective Rho-kinase
inhibitor, for PCI-rela ted refractory myocardial ischemia[J].
Int J Cardiol, 2019, 297:8-13.
[30] Saku K, Kakino T, Arimura T, et al. Left ventricular
mechanical unloading by total support of impella in
myocardial infarction reduces in farctsize, preserves left
ventricular function,and prevents subsequent heart failure in
Dogs[J]. Circ Heart Fail, 2018, 11(5):e004397.
[31] Kapur NK, Alkhouli MA, Demartini TJ, et al. Unloading the
left ventricle before reperfusion in patients with anterior STsegment-
elevation myocar dial infarction[J]. Circulation, 2019,
139(3):337-346.
[32] Hausenloy DJ, Kharbanda RK, M?ller UK, et al. Effect of
remote ischaemic conditioning on clinical outcomes in patients
with acute myocardial infarction (CONDI-2/ERIC-PPCI):
a single-blind randomised controlled trial[J]. Lancet, 2019,
394(10207):1415-1424.
[33] Engstr?m T, Kelb?k H, Helqvist S, et al. Effect of ischemic
postconditioning during primary percutaneous coronary
intervention for patients Wi th ST-segment elevation
myocardial infarction: a randomized clinical trial[J]. JAMA
Cardiol, 2017, 2(5):490-497.
[34] Erlinge D, G?tberg M, Lang I, et al. Rapid endovascular
catheter core cooling combined with cold saline as an adjunct
to percutaneous coronary intervention for the treatment
of acute myocardial infarction.The CHILL-MI trial: a
randomized controlled study of the use of central venous
catheter core cooling combined with cold saline as an adjunct
to percutaneous coronary intervention for the treatment of
acute myocardial infarction[J]. J Am Coll Cardiol, 2014,
63(18):1857-1865.
[35] Noc M, Laanmets P, Neskovic AN, et al. A multicentre,
prospective, randomised controlled trial to assess the
safety and effectiveness of cooling as an adjunctive
therapy to percutaneous intervention in patients with acute
myocardial infarction: the COOL AMI EU Pivotal Trial[J].
EuroIntervention, 2021, 17(6):466-473.
[36] Dai W, Ye Z, Li L, et al. Effect of preoperative loading dose
ticagrelor and clopidogrel on no-reflow phenomenon during
intervention in patients with ST-segment elevation myocardial
infarction undergoing primary percutaneous co ronary
intervention: a systematic review and meta-analysis [J]. Drug
Des Devel Ther, 2018, 12:2039-2049.
[37] David SW, Khan ZA, Patel NC, et al. Evaluation of
intracoronary hyperoxemic oxygen therapy in acute anterior
myocardial infarction: the IC-HOT study[J]. Catheter
Cardiovasc Interv, 2019, 93(5):882-890.
[38] Jeyaraman MM, Rabbani R, Copstein L, et al. Autologous
bone marrow stem cell therapy in patients with ST-elevation
myocardial infarction: a systematic review and metaanalysis[
J]. Can J Cardiol, 2017, 33(12):1611-1623.
[39] Elbaz-Greener G, Sud M, Tzuman O, et al. Adjunctive laserstimulated
stem-cells therapy to primary reperfusion in
acute myocardial infarction in humans: safety and feasibility
study[J]. J Interv Cardiol, 2018, 31(6):711-716.
备注/Memo
- 备注/Memo:
-
基金项目：河北省医学科学研究课题计划项目（20210532）
通信作者：齐晓勇， E-mail:hbghxiaoyong_q@126.com
常用功能
统计/Statistics
- 摘要浏览/Viewed0
- 全文下载/Downloads445
- 评论/Comments
